XML 45 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Data (Tables)
 12 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Areas
Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.  As discussed in Note 10, the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018.
(Millions of dollars)202020192018
United StatesInternationalTotalUnited StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions (a)$1,972 $1,583 $3,555 $2,037 $1,811 $3,848 $1,875 $1,752 $3,627 
Medication Management Solutions (a)1,865 589 2,454 2,115 525 2,640 1,974 513 2,487 
Diabetes Care562 522 1,084 573 538 1,110 564 541 1,105 
Pharmaceutical Systems404 1,184 1,588 392 1,073 1,465 357 1,040 1,397 
Total segment revenues$4,802 $3,878 $8,680 $5,116 $3,947 $9,064 $4,770 $3,846 $8,616 
Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems$769 $718 $1,487 $774 $784 $1,558 $761 $792 $1,553 
Diagnostic Systems1,103 941 2,045 672 875 1,547 678 858 1,536 
Total Integrated Diagnostic Solutions1,872 1,659 3,532 1,446 1,659 3,106 1,438 1,651 3,089 
Biosciences465 678 1,143 485 709 1,194 475 766 1,241 
Total segment revenues$2,337 $2,337 $4,675 $1,931 $2,368 $4,300 $1,914 $2,416 $4,330 
Interventional
Surgery (b)$891 $230 $1,121 $977 $264 $1,242 $820 $202 $1,022 
Peripheral Intervention (b)871 640 1,511 917 657 1,574 728 511 1,239 
Urology and Critical Care (b)815 315 1,130 787 323 1,110 536 240 777 
Total segment revenues$2,577 $1,186 $3,762 $2,682 $1,244 $3,926 $2,084 $953 $3,037 
Total Company revenues$9,716 $7,401 $17,117 $9,730 $7,560 $17,290 $8,768 $7,215 $15,983 
(a)The amounts in fiscal years 2019 and 2018 reflect the reclassification of U.S. revenues of $11 million and $17 million, respectively, associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
(b)The amounts in fiscal years 2019 and 2018 reflect the total reclassifications of $130 million and $134 million, respectively, of U.S. revenues and $55 million and $60 million, respectively, of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.
Financial Information for Company's Segments
(Millions of dollars)202020192018
Income Before Income Taxes
Medical (a) (b) (c) (d)$2,274 $2,824 $2,624 
Life Sciences (e)1,405 1,248 1,207 
Interventional (c) (f)724 903 306 
Total Segment Operating Income
4,403 4,976 4,137 
Acquisitions and other restructurings(309)(480)(740)
Net interest expense(521)(627)(641)
Other unallocated items (g)(2,587)(2,693)(1,583)
Total Income Before Income Taxes$985 $1,176 $1,173 
Assets
Medical$23,007 $22,925 $23,493 
Life Sciences4,713 4,135 4,225 
Interventional21,619 22,157 23,219 
Total Segment Assets49,339 49,217 50,938 
Corporate and All Other (h)4,673 2,548 2,966 
Total Assets$54,012 $51,765 $53,904 
Capital Expenditures
Medical$477 $577 $560 
Life Sciences192 230 255 
Interventional119 120 65 
Corporate and All Other22 30 14 
Total Capital Expenditures$810 $957 $895 
Depreciation and Amortization
Medical$1,104 $1,073 $1,028 
Life Sciences286 284 275 
Interventional750 881 658 
Corporate and All Other14 14 17 
Total Depreciation and Amortization$2,154 $2,253 $1,978 
(a)The amount in 2020 includes a probable estimate of future costs within the Medication Management Solutions unit associated with remediation efforts related to BD AlarisTM infusion pumps of $244 million, which was recorded to Cost of products sold. Based on the course of remediation efforts, it is possible that the estimate of future costs could increase over time. 
(b)The amounts in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.
(c)The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million, respectively.
(d)The amounts in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units; 2018
included $58 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Diabetes Care unit.
(e)The amounts in 2020 included charges of $57 million to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units; 2018 included charges of $81 million to write down the carrying value of certain intangible and other assets in the Biosciences unit.
(f)The amount in 2019 included a charge of $30 million recorded to write down the carrying value of certain intangible assets in the Surgery unit.
(g)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts in 2020 and 2019 included pre-tax charges of $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 11. The amount in 2018 included the pre-tax gain recognized on the Company's sale of its non-controlling interest in Vyaire Medical of approximately $303 million.
(h)Includes cash and investments and corporate assets.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment
Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.
(Millions of dollars)202020192018
Revenues
United States$9,716 $9,730 $8,768 
Europe3,480 3,359 3,298 
Greater Asia2,568 2,726 2,460 
Other1,353 1,476 1,457 
$17,117 $17,290 $15,983 
Long-Lived Assets
United States$36,468 $37,053 $38,982 
Europe5,835 5,483 5,640 
Greater Asia1,521 1,328 851 
Other808 861 645 
Corporate411 377 375 
$45,043 $45,101 $46,494